Verastem Oncology To Report Progress Across VS-7375 Oral KRAS G12D (ON/OFF) TARGET-D Clinical Program And Updated Preliminary Data From Phase 1/2 TARGET-D 101 Dose Escalation And Dose Expansion Trial

Benzinga Newsdesk www.benzinga.com Neutral 94.3%

Neg 0% Neu 94.3% Pos 0%

Featuring updated preliminary clinical data across tumor types from the Phase 1/2 TARGET-D 101 trial

Company to host investor conference call and webcast on Tuesday, June 23, 2026, at 4:30 pm ET

Comments

No comments yet. Be the first!